Equities research analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) in a research report issued on Tuesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Separately, HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a "buy" rating and a $18.00 price objective for the company.
Read Our Latest Stock Analysis on VNDA
Vanda Pharmaceuticals Price Performance
Shares of NASDAQ VNDA traded down $0.10 on Tuesday, hitting $4.94. The company had a trading volume of 189,407 shares, compared to its average volume of 1,258,531. Vanda Pharmaceuticals has a 12-month low of $3.46 and a 12-month high of $6.75. The business has a 50 day moving average of $4.83 and a two-hundred day moving average of $5.26.
Insider Activity at Vanda Pharmaceuticals
In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.90% of the company's stock.
Hedge Funds Weigh In On Vanda Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Monaco Asset Management SAM bought a new position in Vanda Pharmaceuticals in the 2nd quarter valued at about $1,090,000. Dimensional Fund Advisors LP boosted its holdings in shares of Vanda Pharmaceuticals by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company's stock valued at $11,379,000 after acquiring an additional 292,172 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $864,000. GSA Capital Partners LLP acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at approximately $143,000. Finally, Nantahala Capital Management LLC raised its holdings in Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company's stock worth $9,003,000 after purchasing an additional 580,265 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.
Vanda Pharmaceuticals Company Profile
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
See Also
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
